Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

• Published in: Bone marrow transplantation (Basingstoke) Vol. 46; no. 2; pp. 291 - 293
• Main Authors: Naina, H V, Pruthi, R K, Inwards, D J, Dingli, D, Litzow, M R, Ansell, S M, William, H J, Dispenzieri, A, Buadi, F K, Elliott, M A, Gastineau, D A, Gertz, M A, Hayman, S R, Johnston, P B, Lacy, M Q, Micallef, I N, Porrata, L F, Kumar, S
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.02.2011; Nature Publishing Group
• Subjects: 631/45/127; 692/699/75/567; 692/700/565/1331; Adolescent; Adult; Aged; Amyloidosis; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Blood and lymphatic vessels; Bone marrow; Bone marrow, stem cells transplantation. Graft versus host reaction; Cardiology. Vascular system; Catheters; Cell Biology; Diagnosis; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Embolism; Female; Granulocyte colony-stimulating factor; Granulocyte Colony-Stimulating Factor - adverse effects; Granulocytes; Growth factors; Hematology; Hematopoietic Stem Cell Mobilization; Hematopoietic stem cells; Heparin; Hodgkin's lymphoma; Humans; Internal Medicine; Leukocytes (granulocytic); Lymphoma; Male; Medical instruments; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Multiple myeloma; original-article; Physiological aspects; Public Health; Pulmonary embolism; Risk; Risk factors; Stem cell transplantation; Stem Cells; Thrombocytopenia; Thromboembolism; Thrombosis; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Venous Thromboembolism - etiology; United States; stem cell mobilization; G-CSF; venous thrombosis; Hematology; Stem cell; Cardiovascular disease; Low risk; Embolism; Venous disease; Vascular disease; Mobilization; Granulocyte colony stimulating factor; Blood vessel; Venous thrombosis; Circulatory system; Thromboembolism; Vein; Growth factor
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/bmt.2010.106

The use of erythropoietic agents has been associated with an increased risk of venous thromboembolic events (VTEs), especially in patients with underlying malignancies. However, it is not known whether there is an increased risk of VTE associated with granulocyte growth factors. We reviewed 621 patients undergoing PBSC mobilization using granulocyte growth factors, alone or in combination with CY. Patients with a diagnosis of AL amyloidosis (AL: 114; 18%), multiple myeloma (MM: 278; 44%) Hodgkin lymphoma (HL: 20; 3%) or non-Hodgkin lymphoma (NHL: 209; 33%) were included. Symptomatic VTE occurred in six (0.97%) patients: two AL, two MM and two NHL. Of the six patients, two had pulmonary embolism, one developed deep vein thrombosis and three developed symptomatic catheter related thrombosis. Two patients with AL had heparin-induced thrombocytopenia and thrombosis. We found a low incidence of VTE among patients undergoing PBSC mobilization.